Herceptin

Herceptin shows biosimilar markets can work. To what extent is the question.
Medical Marketing and Media
Sun, 06/11/23 - 11:12 pm
Herceptin
biosimilars
Study: Biosimilars ‘fulfilling their promise’ of lowering biologic prices
BioSpace
Wed, 06/7/23 - 11:22 am
biosimilars
biologics
drug pricing
Roche
Herceptin
Amgen
Kanjinti
Viatris
Ogivri
Pfizer
Trazimera
Teva Pharmaceutical
Herzuma
Organon
Ontruzant
Merck's Blockbuster Cancer Antibody Racks Up Another Approval
BioSpace
Thu, 05/6/21 - 10:59 pm
Merck
Keytruda
FDA
Herceptin
gastric adenocarcinoma
AZ/Daiichi Sankyo’s Enhertu gets second US cancer indication
Pharmaforum
Mon, 01/18/21 - 01:15 pm
AstraZeneca
Daiichi Sankyo
stomach cancer
Enhertu
Roche
Herceptin
MacroGenics wins FDA approval of breast cancer drug
BioPharma Dive
Thu, 12/17/20 - 06:15 pm
Margenza
Macrogenics
FDA
breast cancer
Roche
Herceptin
Merck launches Herceptin biosimilar in U.S.
Seeking Alpha
Wed, 04/15/20 - 10:55 am
Merck
Herceptin
Roche
biosimilar
Ontruzant
Pfizer launches biosimilars to Roche’s ‘big three’ cancer drugs in US
Pharmaforum
Fri, 01/24/20 - 10:11 am
Pfizer
Roche
biosimilars
Avastin
Zirabev
Herceptin
Trazimera
Rituxan
Ruxience
WHO Prequalifies its First Biosimilar
RAPS.org
Thu, 12/19/19 - 06:01 pm
WHO
biosimilars
Samsung Bioepis
Ontruzant
Roche
Herceptin
breast cancer
Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer
Pharmaceutical Business Review
Fri, 12/13/19 - 12:20 pm
Roche
Perjeta
Herceptin
HER2+ breast cancer
SABCS
breast cancer
SABCS: Roche's Perjeta builds case as add-on to Herceptin with new analysis
Fierce Pharma
Wed, 12/11/19 - 10:35 am
Roche
breast cancer
Herceptin
Perjeta
biosimilars
SABCS
Roche under fire again: Mylan launches Herceptin copycat in latest blow to blockbuster trio
Fierce Pharma
Tue, 12/3/19 - 10:02 am
Roche
Mylan
Herceptin
biosimilar
cancer
oncology
Ogivri
Daiichi Sankyo takes Seattle Genetics to court as battle over breast cancer drug escalates
Pharmaforum
Wed, 11/6/19 - 10:18 am
Daiichi Sankyo
Seattle Genetics
breast cancer
AstraZeneca
trastuzumab deruxtecan
Herceptin
SITC 2019 preview – Pieris joins the quest for a better Herceptin
EP Vantage
Mon, 11/4/19 - 07:22 pm
SITC
Pieris
Herceptin
PRS-343
As ‘big three’ oncology meds lose sales, Roche looks to file subcutaneous breast cancer combo
Pharmaforum
Fri, 09/13/19 - 10:56 am
Roche
Perjeta
Herceptin
Genentech
HER2-positive breast cancer
Amgen biosimilar debut boosted by UnitedHealthcare coverage switch
Biopharma Dive
Mon, 08/19/19 - 11:52 am
insurers
Amgen
biosimilars
Avastin
Herceptin
Roche
UnitedHealthcare
Roche doomsday is here: Long-feared Herceptin, Avastin biosims bust into U.S. market
Fierce Pharma
Fri, 07/19/19 - 07:28 pm
Herceptin
Avastin
Roche
biosimilars
Allergan
Amgen
FDA Approves 20th Biosimilar, 5th for Roche’s Herceptin
RAPS.org
Thu, 06/13/19 - 10:37 pm
FDA
biosimilars
Roche
Herceptin
Amgen
Kanjinti
Pfizer gets FDA approval for oncology biosimilar Trazimera
Pharmaceutical Business Review
Tue, 03/12/19 - 11:33 am
Pfizer
FDA
Trazimera
Genentech
biosimilars
Herceptin
Top 10 drugs losing exclusivity in 2019
Fierce Pharma
Tue, 03/5/19 - 09:40 am
market exclusivity
patents
Rituxan
Lyrica
Herceptin
Avastin
Epclusa
Harvoni
Pfizer
Roche
Gilead Sciences
Amgen
GSK
Allergan
Individor
Roche wins US approval of more convenient Herceptin
Biopharma Dive
Sat, 03/2/19 - 12:03 am
Roche
Herceptin
breast cancer

Pages